Tender detail
New active substances for itemised reimbursement
Summary
Hungary’s National Health Insurance Fund Management procures medicines containing 11 active substances for healthcare institutions under framework agreements. The lots cover trastuzumab emtansine, pertuzumab, trastuzumab deruxtecan, anifrolumab, nivolumab with relatlimab, deucravacitinib, tucatinib, zanubrutinib, encorafenib, binimetinib and filgotinib. Each lot has a stated base quantity and an optional additional quantity, with supplies intended for the treatment of patients in the relevant therapeutic areas.
More tender information after sign-in
The public view shows key tender details. Sign in to open official links, documents and AI tender support.